These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors. Dunn A Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344 [No Abstract] [Full Text] [Related]
3. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis. Glaser R; Glick HA; Herrmann HC; Kimmel SE J Am Coll Cardiol; 2006 Feb; 47(3):529-37. PubMed ID: 16458131 [TBL] [Abstract][Full Text] [Related]
4. GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us. Chew DP; Moliterno DJ Cleve Clin J Med; 2001 Dec; 68(12):1017-23. PubMed ID: 11765119 [TBL] [Abstract][Full Text] [Related]
5. Emergency coronary artery bypass grafting in patients with acute myocardial infarction treated with glycoprotein IIb/IIIa receptor inhibitors. De Carlo M; Maselli D; Cortese B; Ciabatti N; Gistri R; Levantino M; Balbarini A; De Caterina R; Petronio AS Int J Cardiol; 2008 Jan; 123(3):229-33. PubMed ID: 17433463 [TBL] [Abstract][Full Text] [Related]
6. Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: IIb or Not IIb, what is the question? Young JJ; Kereiakes DJ J Invasive Cardiol; 2002 Jul; 14(7):404-10. PubMed ID: 12082194 [TBL] [Abstract][Full Text] [Related]
11. [Impact of GP IIb/IIIa antagonists in interventional cardiology]. Scheller B; Hennen B; Böhm M; Nickenig G Dtsch Med Wochenschr; 2003 Feb; 128(6):281-7. PubMed ID: 12571800 [No Abstract] [Full Text] [Related]
12. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing. Hobbach HP; Schuster P Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467 [TBL] [Abstract][Full Text] [Related]
14. Platelet glycoprotein IIb/IIIa inhibition as adjunctive therapy during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Young JJ J Invasive Cardiol; 2005 Jun; 17(6):300-1. PubMed ID: 16003003 [No Abstract] [Full Text] [Related]
15. Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban. King S; Short M; Harmon C Vascul Pharmacol; 2016 Mar; 78():10-6. PubMed ID: 26187354 [TBL] [Abstract][Full Text] [Related]
16. Platelet glycoprotein IIb/IIIa receptor inhibitors--end of an era? Roffi M; Mukherjee D Eur Heart J; 2008 Feb; 29(4):429-31. PubMed ID: 18276614 [No Abstract] [Full Text] [Related]